Q1FY19 Result: Suven Life Sciences PAT jumps 31 per cent

Suven Life Sciences reported its results for the quarter ended June 30, 2018. The company’s standalone revenue for the quarter came in at Rs. 191.66 crore, registering 35.9 per cent yoy increase. This was mainly driven by a jump in revenue from the manufacturing segment by 35.2 per cent yoy.

EBITDA for the quarter rose by 31.3 per cent yoy to Rs. 56.09 crore with a corresponding margin contraction of 103 bps. EBITDA margin for the quarter stood at 29.3 per cent. The PAT for the quarter came in at Rs. 38.84 crore, yoy increase of 31 per cent.

Earlier, the company had announced the successful grant of one product patent from Mexico and New Zealand each.

Suven Life Sciences is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are CNS therapies using GPCR targets.

On Thursday, the stock opened at Rs. 238 per share and made an intraday high and low of Rs. 241 and Rs. 229.20, respectively, on the BSE.